PubMed HealthSearch

PubMed · 978444

Computerized automated system for determining dissolution rate profiles for solid dosage forms.

Abstract

A unique automated system was developed for the measurement of dissolution rates of tablets and capsules. This system, which adheres to principles set forth in the compendia, can test six dosage forms simultaneously. It is modular in form and capable of maintaining sink conditions, and it can handle any type of chemistry amenable to an automatic analyzer. In addition to the usual dissolution apparatus, the system includes a 12-channel combination sampling and solvent addition pump, a sequence control module, pertinent automated analyzer components, a spectrophotometer or fluorometer, an optional recorder, a specially designed digitizing system, and a teletype equipped with a paper tape punch reader and acoustic coupler. Each dissolution flask is automatically sampled every 6 min. Standards may be run either before or after the samples. Since dissolution, sampling, chemistry, and readout are all accomplished simultaneously, the complete test time is essentially reduced to the dissolution time itself. At the completion of sample dissolution, raw dissolution profile data are on the punched paper tape ready for computer processing via a time-sharing system. Developed software provides for the printout of a complete test report in less than 15 min.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

F J Cioffi, H M Abdou, A T Warren. 1976. Computerized automated system for determining dissolution rate profiles for solid dosage forms.. https://doi.org/10.1002/jps.2600650826

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effects of sotalol on the signal-averaged electrocardiogram in patients with sustained ventricular tachycardia: relation to suppression of inducibility and changes in tachycardia cycle length.

OBJECTIVES: This study examines the effects of sotalol on the signal-averaged electrocardiogram (ECG) in patients with spontaneous and inducible sustained ventricular tachycardia and correlates these findings with the effect of sotalol on tachycardia inducibility and tachycardia rate. BACKGROUND: Standard electrocardiography generally does not detect any change in the duration of the QRS complex resulting from sotalol therapy. However, the signal-averaged ECG is more sensitive than the standard ECG for detecting changes in QRS duration induced by antiarrhythmic drugs and can also detect changes in late potential duration. METHODS: Signal-averaged electrocardiography was performed before therapy in 30 patients with spontaneous and inducible ventricular tachycardia, and both electrophysiologic study and a signal-averaged ECG were repeated during therapy with d,l-sotalol. RESULTS: During sotalol therapy the signal-averaged QRS duration decreased by 2.6 +/- 6.6 ms in the 11 patients with no inducible tachycardia during therapy, whereas it increased by 3.8 +/- 5.8 ms (p = 0.01) in the 19 patients with inducible tachycardia during therapy. In the latter group there was a significant positive correlation between prolongation of tachycardia cycle length and prolongation of late potential duration by sotalol (r = 0.56, p = 0.01). CONCLUSIONS: Sotalol can alter QRS and late potential duration as measured by the signal-averaged ECG. Prolongation of QRS duration or late potential duration may reflect a slowing of conduction by sotalol that may interfere with this agent's antiarrhythmic efficacy and slow ventricular tachycardia.

Capsules